VDC2008 + cyclophosphamide

**VDC2008 + cyclophosphamide** is a combination regimen consisting of the investigational agent VDC2008 and the established chemotherapy drug cyclophosphamide. Cyclophosphamide is a small molecule alkylating agent widely used in oncology and immunosuppression; it acts by crosslinking DNA strands, leading to cytotoxicity in proliferating cells. Its mechanism also involves immunomodulatory effects, reducing T cell regulatory activity and influencing cytokine profiles. The mechanism of action, modality, and molecular targets of VDC2008 are not defined in the provided sources; therefore, all mechanistic and developer information relates specifically to cyclophosphamide. Cyclophosphamide is used for multiple cancers (such as lymphoma, leukemia, multiple myeloma, breast and ovarian cancers), as well as certain autoimmune and immune-mediated diseases. It is administered via oral or intravenous routes. VDC2008's use in combination may be designed to enhance anti-tumor activity or modulate immune responses, but its specific mechanism, modality, and developer are not established in current public sources[1][2][3][4][6][7][8][9].

Other names

VDC2008 + cyclophosphamide